KRAS and lung carcinoma: Strikingly, T cells and/or B cells are required for durable responses to KRAS inhibitors in mouse models of lung cancer, colorectal cancer, and PDAC (12, 54, 58), suggesting that the priming of an adaptive immune response may efficiently eliminate drug resistant cells.